Clinical trial
Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With…
NCT00236119 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00236119 |
|---|---|
| Title | Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis |
| Official title | A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe, Recalcitrant, Plaque Type Psoriasis |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | CEP-701 20mg, CEP-701 40mg, CEP-701 60mg, CEP-701 80mg |
| Enrollment | 46 |
| Start date | Jun 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Oct 12, 2005 |
| Last update posted | Aug 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: